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igraines  are  common  illnesses.  Studies  conducted  in  12
atin  American  cities,  including  two  in  Mexico,  have  found
hat  its  prevalence  in  our  country  is  15%.  The  rate  in  gender
s  3:1  (Women/Men)  worldwide.
The  diagnostic  criteria  for  migraines  were  published  for
he  ﬁrst  time  in  1988,  in  the  ﬁrst  edition  of  the  International
eadache  Classiﬁcation,  promoted  by  the  International
eadache  Society,  with  its  second  edition  in  2003,  and
 third  beta  version  that  will  probably  be  published  in
015.  Diagnostic  criteria  for  the  different  forms  of  migraines
ere  ﬁrst  described  in  this  document,  which  has  simpliﬁed
ommunication  among  doctors  and  made  possible  compar-
sons  between  studies.  The  current  migraine  criteria  (with
nd  without  aura)  are  shown  in  Table  1.
As  in  all  primary  headaches,  paraclinic  and  imaging  stud-
es  are  normal  and  rarely  necessary,  exception  made  for  the
ases  where  there  is  clinical  doubt  or  whenever  the  patient
s  too  anxious  and  wishes  to  be  ‘‘as  certain  as  you  can  be’’.
his  may  be  a  valid  reason;  however  it  may  increase  the  cost
f  medical  attention  and  can  be  problematic  in  institutions
ith  a  high  volume  of  patients.
The  management  of  migraines  must  contemplate  two
spects:
.  Acute  management  (abortive).
. Preventive  management.
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harmacological  measures  must  be  contemplated.
anagement generalities
efore  beginning  management  of  a migraine,  as  in  any  other
athological  entity,  we  must  ask  ourselves,  several  ques-
ions:
.  Are  medications  necessary?
.  If  so,  are  there  parameters  to  choose  one  as  the  best?
.  How  will  results  be  measured?
.  Which  will  the  success  and  failure  criteria  be  to  decide
a  change  in  management?  In  other  words,  how  long  to
maintain  a  medication  before  considering  it  did  not  work.
.  How  long  will  a  successful  treatment  last?
.  What  is  the  a  priori  probability  of  recovery/recurrence?
Answering  each  and  every  one  of  these  questions  before
eginning  management  is  fundamental.  It  gives  the  man-
gement  sense  and  direction,  for  both  the  doctor  as  well
s  the  patient.  Additionally,  it  brings  the  patient  the  feel-
ng  that  he/she  is  able  to  do  something,  or  cooperate  in  the
reatment,  and  thus  the  patient  perceives  he/she  has  some
ontrol  over  his/her  illness.
bortive management
eneral  guidelines:.  To  treat  as  early  as  possible.  The  instruction  is:  ‘‘Take  the
medication,  or  do  as  indicated,  as  soon  as  the  patient
recognizes  if  a  crisis  arises.’’  Patients  learn  to  recog-
nize  when  this  happens,  and  we  know  that  abortive
asson Doyma México S.A. This is an open access article under the
.0/).
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Table  1  Diagnostic  criteria  of  frequent  migraines.
Migraine  without  aura
A. At  least  ﬁve  attacksfulﬁlling  criteria  B--D
B. Headache  attacks  lasting  4--72  hours  (untreated  or  unsuccessfully  treated)
C. Headache  has  at  least  two  of  the  following  four  characteristics:
1. unilateral  location
2. pulsating  quality
3. moderate  or  severe  pain  intensity
4. aggravation  by  or  causing  avoidance  of  routine  physical  activity  (e.g.  walking  or  climbing  stairs)
D. During  headache  at  least  one  of  the  following:
1. nausea  and/or  vomiting
2. Photophobia  and  phonophobia
E. Not  better  accounted  for  by  another  ICHD-3  diagnosis.
Migraine  with  Aura
A.  At  least  two  attacks  fulﬁlling  criteria  B  and  C
B. One  or  more  of  the  following  fully  reversible  aura  symptoms:
1. visual
2. sensory
3. speech  and/or  language
4. motor
5. brainstem
6. retinal
C. At  least  two  of  the  following  four  characteristics:
1. one  aura  symptom  spreads  gradually  over  5  minutes,  and/or  two  or  more  occur  in  succession
2. each  individual  aura  symptom  lasts  5--60  minutes
3. at  least  one  aura  symptom  is  unilateral
4. the  aura  is  accompanied,  or  followed  within  60  minutes,  by  headache
D. Not  better  accounted  for  by  another  ICHD-3  diagnosis,  and  transient  ischaemic  attack  has  been  excluded.
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Ttreatment  loses  effect  in  a  direct  proportion  to  the  delay
in  treatment.
2.  To  have  a  record  of  the  amount  of  analgesic  used.  Set
limits  and  have  a  ‘‘plan  B’’  and  ‘‘plan  C’’  ready  in  case
of  acute  therapeutic  failure.
3.  If  we  are  going  to  try  a  medication  (i.e.  a  triptan),  try
it  in  at  least  two  crises  before  declaring  therapeutic
failure.
4.  Remember  that  the  abortive  treatment  is  exactly  that:
abortive.  Although  there  are  exceptions;  it  must  not  be
used  with  a  schedule.  The  principle  is  to  NEVER  give
abortive  medication  on  a  schedule.  Exceptions  would  be
situations  where  we  can  anticipate  the  onset  of  the  crisis,
like  migraines  associated  with  menstruation  (with  regu-
lar  cycles)  or  episodic  cluster  headache.  In  general,  the
evolution  of  the  crisis  in  most  migraines  is  predictable;
thus  the  patient  is  able  to  know  when  to  take  the
medication.
Non-pharmacological  measures
Some  patients  learn  some  techniques  which  can  help  attenu-
ate  the  pain  or  make  it  disappear.  The  most  utilized  method
is  sleep.  The  physician  can  try  to  compress  both  superﬁcial
temporal  arteries  in  front  of  the  tragus  (or  on  the  side  where
there  is  pain,  if  it  is  hemicranial)  in  order  to  try  to  abort  the
t
h
e
rrisis.  Its  effectiveness  is  estimated  to  be  between  30%  and
0%.
Diet  is  reserved  for  those  cases  where  there  is  a  close
emporal  relationship  between  the  dietary  element  imputed
nd  the  onset  of  the  crisis.  There  is  no  point  in  giv-
ng  a  restrictive  diet  a  priori. The  idea  of  prohibiting
he  consumption  of  speciﬁc  food,  like  chocolate,  cheese,
anned  foods,  sausages,  Chinese  food,  wine  (especially  red)
r  any  form  of  alcohol,  among  others,  is  highly  popu-
ar.  The  experience  in  our  center  is  that  food  trigger  are
are.
A  careful  interrogatory  is  the  best  tool  to  indicate
 restrictive  diet.  Therefore,  it  is  mandatory  to  keep
 headache  diary  where  the  patient  must  record  the
umber  of  attacks,  intensity,  time,  response  to  medica-
ions,  and  relationship  to  external  events  or  foods.  This
iary  will  give  us  the  parameters  to  make  changes  in
anagement.
edications
he  best  results  of  abortive  treatment  are  with  medica-
ions.  Individual  sensitivity  to  a medication  is  unpredictable;
owever,  we  have  probabilities  of  effectiveness.  The  most
ffective  medications  are  triptans,  and  within  this  group,
izatriptan  and  eletriptan  have  the  most  favorable  evidence.
1 A.  Marﬁl
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Table  2  Level  of  evidence  for  preventive  medicines.
Level  A:  Medications  with  a  well-established  efﬁciency
(≥2 Class  1  clinical  trials)
A. Antiepileptics:  Divalproex  sodium,  topiramate
sodium  valproate
B. Beta  blockers:  metoprolol,  propranolol,  timolol
C. Triptans:  frovatriptan
Level  B:  Medications  that  are  likely  to  be  effective  (1
class 1  study/2  class  2  studies)
A. Antidepressants/SISRs/SISNRs/ATT:  Amitriptyline,
venlafaxine
B. Beta  blockers:  atenolol,  nadolol
C. Triptans:  naratriptan,  zolmitriptan
Level  C:  Possibly  effective  medications  (one  class  2
study)
A. ACEIs:  lisinopril
B.  ARAs:  candesartan
C.  Alpha  agonists:  clonidine,  guaifenesin
D. Antiepileptics:  carbamazepina
E. Beta  blockers:  nebivolol,  pindolol
F. Antihistamines:  cirpoheptadina
Level  U:  Insufﬁcient  or  inadequate  data  to  make
recommendations
A. Carbonic  anhydrase  inhibitor:  acetazolamide
B. Antithrombotics:  acenocoumarol,  coumadin,
picotamide
C. Antidepressants  SISRs/SISNRs:  ﬂuvoxamine,
ﬂuoxetine
D. Antiepileptics:  gabapentin
E. Tricyclics:  protriptyline
F. Beta  blockers:  bisoprolol
G. Ca  channel  blockers:  nicardipine,  nifedipine,
nimodipine,  verapamil
H. Vascular  smooth  muscle  relaxants:  cyclandelate
Other:  Medications  established  as  possibly/probably
ineffective
A. Established  as  ineffective:  lamotrigine
B. Probably  ineffective:  clomipramine
C.  Possibly  ineffective:  acebutolol,  clonazepam,
nabumetone,  oxcarbazepine,  telmisartan
ACEIs: angiotensin converting enzyme inhibitors; ARAs:
angiotensin receptor antagonists; SISRs: selective inhibitors of
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owever,  there  is  no  way  of  predicting  the  result  of  a  partic-
lar  medication  in  a  particular  patient.  Furthermore,  failure
f  one  triptan  does  not  predict  the  failure  of  another,  thus
rying  out  two  or  three  different  triptans  may  be  justi-
ed.  Our  protocol  is  to  start  with  one  of  these  two,  to
ry  it  for  at  least  2  crises,  and  decide  whether  or  not
hey  worked.  If  they  did  not  work,  switch  to  a  different
riptan.  The  instruction  to  the  patient  is:  take  (or  place
he  wafer  of  rizatriptan  or  zolmitriptan  over/under  the
ongue)  the  medication  as  soon  as  the  patient  recognizes
he  onset  of  a  crisis.  Keep  in  mind  that  the  effectiveness
f  the  medication  decreases  with  the  interval  before  tak-
ng  it;  once  the  ﬁrst  dosage  of  medication  is  taken  we  ask
hem  to  wait  for  an  hour;  if  at  the  end  of  the  hour  the
risis  is  not  over,  take  the  second  dose.  If  after  the  sec-
nd  hour  (an  hour  after  the  second  dose),  the  crisis  has
ot  disappeared,  begin  with  a  second,  different,  medica-
ion.  The  concept  of  ‘‘crisis  disappearance’’  is  precisely
hat:  to  completely  stop  not  only  the  pain  (which  should
ompletely  disappear),  but  also  the  autonomic  and  cog-
itive  symptoms,  etc.  If  residual  symptoms  persist,  the
robability  of  recurrence  is  greater.  Recurrence  is  deﬁned
s  the  reappearance  of  a  crisis  in  a  period  shorter  than
4  h  from  treatment.  It  is  important  to  remember  that  all
bortive  medications,  if  used  frequently,  can  cause  rebound
eadaches.  Thus  the  need  to  keep  track  of  any  medication
hat  the  patient  may  take,  even  if  they  are  over-the-counter
edications.
Ergotamine  is  also  effective  and  low-cost,  making  it
 good  option  for  institutions  with  a  high  volume  of
atients.  It  has  an  effectiveness  of  40--60%  in  pain  reduc-
ion/disappearance.  The  main  problem  is  that  it  is  highly
ddictive  and  we  must  take  all  precautions  when  utiliz-
ng  potentially  addictive  drugs:  keep  track  of  medication,
upervise  prescriptions,  and  review  results  frequently.  Indi-
ations  to  the  patient  are:  initiate  treatment  as  soon  as  a
risis  is  recognized;  start  with  1  mg  of  the  usual  presenta-
ions  (two  tablets  of  0.5  mg)  and  give  an  additional  0.5  mg
very  half  hour  until  one  of  these  three  things  occur:  the
risis  aborts,  the  patient  starts  vomiting,  or  6  tablets  (3  mg)
re  taken.  The  consumption  of  more  than  6  tablets  in  a  24  h
eriod,  or  16  (8  mg)  in  a  week  is  the  threshold  to  develop
ebound  headaches,  in  addition  to  increasing  the  risk  of
ddiction.  If  the  episode  ceases  at,  let  us  suppose,  2  mg
four  tablets),  and  the  pain  returns  within  the  following  24  h,
edication  will  be  given  to  the  patient  ‘‘as  if  it  were  the
ext  half  an  hour’’  If  longer,  it  will  be  considered  as  a  new
pisode.
Over-the-counter  medications  are  commonly  utilized,
otu  proprio,  by  patients.  Many  learn  that  certain  med-
cations  or  a  combination  of  analgesics  give  them  relief
r  abort  the  crisis.  The  problem  with  self-medication  is
hat  it  is  the  single  most  important  factor  for  chroniﬁca-
ion  and  the  transformation  of  an  episodic  migraine  to  a
hronic  one.  There  will  always  be  the  need  to  investigate
he  use,  dosage,  frequency,  etc.  of  such  self-medication.
he  same  principle  applies  with  ‘‘natural’’  medications  or
erbal  medicine.  The  physician  should  intentionally  ask  for
heir  use  because  there  may  be  active  pharmacological  prin-
iples  that  can  complicate  the  evolution  or  result  of  the
reatment.
T
p
cserotonin recovery; SISNR: selective inhibitors of serotonin and
norepinephrine recovery.
It  is  important  to  keep  in  mind  that  the  ideal  objective  of
reatment  is  not  to  use  abortive  medications,  because  there
re  no  more  episodes.
It  is  important  not  to  mix  ergotamines  and  triptans  in  the
ame  session  of  treatment.  It  is  a  paramount  contraindica-
ion  that  one  must  keep  in  mind.
reventive treatmenthere  are  publications  of  international  guidelines  for
reventive  management  of  episodic  migraines  with  medi-
ations.  Table  2  shows  the  different  groups  of  drugs  with
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their  levels  of  evidence  from  the  American  Academy  of  Neu-
rology  guidelines, 1 that  in  general  agree  with  the  rest  of
international  organizations.
In  our  country  there  is  no  hard  data  on  the  effec-
tiveness  of  medications  in  our  population,  however  there
is  some  useful  information.  In  2005,  the  Headache  Study
Group  of  the  Mexican  Academy  of  Neurology  published
a  consensus  on  the  management  of  migraines.  Combin-
ing  experiences,  we  proposed  that  our  population  required
lower  doses  than  those  published.  This  data  has  been  com-
mented  on  international  meetings  and  our  colleagues  in
Latin  America  and  Spain  concur  with  the  impression  that  the
doses  generally  needed  in  our  respective  populations  are
lower.  Regarding  the  preferences  of  medications,  in  2008
our  group  conducted  a  national  survey  on  the  behavior  of
neurologists  and  neuropediatricians  in  the  management  of
migraines.2
Non  pharmacological  treatment
As  mentioned  above,  one  must  identify  the  individual  trigg-
ering  factors,  should  there  exist.  Even  though  they  are
not  very  frequent,  they  can  be:  dietary  elements,  lack
or  excess  of  sleep,  irregular  meal  times,  and  exposure  to
intense  light.  The  causal  relationship  between  stress  and
the  production  of  a  crisis  is  hard  to  prove,  even  if  it  is
an  idea  that  ‘‘sounds  good’’.  Obesity  has  been  proven
as  a  risk  factor  for  migraine  chroniﬁcation  and  dimin-
ished  response  to  medication.  Thus  it  is  recommended,
as  in  other  situations,  to  comply  with  general  rules  of
hygiene.
Preventive  medications
In  Table  2  there  is  a  list  of  medications  with  better  evidence.
The  recommendations  for  non-neurologists  are:
1.  Always  keep  a  ‘‘headache  diary’’  recording  the  number
of  crises,  intensity,  duration,  time,  associated  symp-
toms,  triggers,  effect  of  used  medications,  unwanted
or  adverse  effects,  need  of  rescue  medication  and  days
without  pain.  It  is  fundamental  in  order  to  assess  the
result  of  the  treatment.  Aside  from  this,  the  MIDAS
scale  can  be  used  to  assess  the  impact  of  the  disease
on  activities  of  daily  living.
2.  There  are  no  speciﬁc  guidelines  or  criteria  to  start  a
preventive  treatment.  In  general,  we  take  into  account
the  number  of  crises  and  the  impact  on  quality  of  life.
With  two  or  more  crises  per  month  the  risk/beneﬁt  ratio
of  medications  is  considered  satisfactory  to  justify  the
beginning  of  treatment.  In  some  people  (i.e.  women
with  migraines  associated  with  menstruation  and  reg-
ular  cycles)  we  are  able  to  begin  ‘‘short  preventive
treatments’’,  three  days  before  and  after  the  expected
onset  of  the  crisis,  in  each  cycle.  The  same  happens  in
other  types  of  headaches  where  we  are  able  to  predict
the  onset  of  a  crisis.
3.  Learn  to  manage  two  or  three  medications  well.  Prefer-
ably  from  two  different  groups.
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4.  Consider  comorbidities.  Rule  out  if  the  patient  is
hypertensive,  suffers  from  asthma,  anxiety,  depression,
obesity  or  other  conditions  that  may  indicate  or  con-
traindicate  a speciﬁc  medication.
5.  Encourage  the  patient  to  comply  with  non-
pharmacological  measures:  enough  sleep,  regular
meal  schedules,  weight  loss,  regular  exercise,  avoiding
excesses  of  food,  drinks  and  alcohol  and  other  general
hygiene  measures.
6.  Establish,  along  with  the  patient,  a  treatment  plan  with
speciﬁc  measurable  goals  and  commit  him  to  accom-
plishing  them.  The  incidence  of  non  compliance  or
abandonment  of  treatments  is  high  and  should  always
be  investigated  in  each  visit,  since  it  may  be  a  cause  of
therapeutic  failure.
7. There  is  not  a  guideline  or  speciﬁc  evidence  on  the
duration  of  a  successful  treatment.  The  intervals  vary.
In  our  national  survey,  most  neurologists  and  pedia-
tricians  considered  maintaining  a  successful  treatment
for  6--8  months.  However,  there  were  responses  from
3  to  12  months.  In  general,  a treatment  is  planned
to  last  8  months  without  a  crisis. The  ﬁrst  two
months  are  useful  to  assess  the  effectiveness  of  the
medication.
8.  At  the  beginning  of  treatment  we  know  there  is  a  prob-
ability  of  effectiveness.  We  must  maintain  the  use  of
a  medication  for  at  least  two  months  at  proper  doses
before  deciding  it  is  not  working.  A  frequent  cause  of
‘‘treatment  failure’’  is  not  giving  it  enough  time  to
work.  This  should  be  clearly  explained  to  the  patient
so  that  he/she  cooperates  during  this  period  and  exert
enough  patience.
9.  At  the  end  of  the  planned  period,  stop  the  medication
and  observe.  The  rate  of  recurrence  is  30--40%.
0.  While  the  goal  is  zero  crises,  sometimes  a few  may  be
tolerated,  either  because  of  low  tolerability  of  the  med-
ication  or  because  the  patient  is  reluctant  to  increase
the  dose.  In  these  cases  there  are  no  speciﬁc  num-
bers  about  the  cure/recurrence  rate  after  completing
a  treatment.  We  must  explain  to  the  patient  that
migraines  are  diseases  that  tend  to  recur  in  different
epochs  in  life.
1.  In  case  of  recurrence  after  a  successful  treatment
(months  or  years  later),  the  most  reasonable  thing  to
do  is  to  restart  the  treatment  which  was  useful.
Migraines  are  a  condition  which  can  be  controlled  and,
ometimes  ‘‘cured’’.  We  ought  to  understand  that  the
oncept  of  curing  is  similar  to  that  of  other  chronic
onditions  of  difﬁcult  prognosis  (rheumatics,  oncological,
tc.),  which  is  the  absence  of  recurrence  in  a  deter-
ined  period  of  time  after  treatment.  The  doctor  should
ay  attention  to  the  details  of  the  treatment  in  order
o  communicate  to  the  patient  what  he  is  trying  to
e  accomplish,  and  thus  be  able  to  gain  his  trust  and
ooperation.onﬂict of interest
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